Nucala costs roughly $3,991 per dose at list price, and since it’s taken monthly, that adds up to nearly $48,000 a year before insurance. Even compared to other biologics in its class, Nucala sits at the higher end. The price reflects several reinforcing factors: the sheer complexity of manufacturing a biologic drug, limited competition, the US drug pricing system, and the cost of developing a treatment for a relatively small patient population.
What a Year of Nucala Actually Costs
GSK lists the price of a single self-injectable dose of Nucala at $3,990.98 as of early 2026. For severe eosinophilic asthma, the most common use, dosing is once every four weeks. That puts the annual wholesale cost close to $48,000 before any insurance negotiation or copay assistance.
That’s not what most patients pay out of pocket, but it is the starting number that shapes everything downstream: what insurers negotiate, what your copay looks like, and why prior authorization hoops exist. Nucala is also approved for nasal polyps, a rare blood vessel disease called EGPA, hypereosinophilic syndrome, and COPD, each with its own dosing schedule. The monthly cost can shift depending on which condition is being treated.
Biologics Are Fundamentally Different to Make
The biggest driver of Nucala’s price is that it’s a biologic, not a traditional pill. Conventional drugs are small molecules built through chemical reactions. Biologics like Nucala are monoclonal antibodies: large, complex proteins grown inside living cells. That distinction changes everything about how the drug is produced.
Nucala is manufactured using Chinese Hamster Ovary (CHO) cells, the industry standard for monoclonal antibody production. These cells are cultured in massive bioreactors under tightly controlled conditions. The cell culture medium alone can cost on the order of $1 million per batch. Once the cells produce the antibody, it has to be extracted and purified through multiple steps, including specialized chromatography that uses resins costing millions of dollars for a single large batch. Virus filtration membranes used in the process are single-use and expensive. Even the buffers, the chemical solutions used throughout processing, add meaningful cost.
The facilities themselves are capital-intensive. Many biopharmaceutical manufacturing plants were built with stainless steel equipment designed to produce a single product, requiring enormous upfront investment and long lead times. These plants typically run at about 70% of their maximum capacity. Unlike a chemical drug factory that can be retooled relatively quickly, biologic manufacturing infrastructure is specialized and inflexible. All of this helps explain why the production cost for monoclonal antibodies remains above $50 per gram of drug substance, a floor that has proven stubbornly difficult to lower.
A Small Patient Pool Means Higher Per-Patient Costs
Nucala targets a specific subset of patients: those with eosinophil-driven diseases. Severe eosinophilic asthma, its primary indication, affects a fraction of the total asthma population. The other approved conditions (EGPA, hypereosinophilic syndrome, nasal polyps with specific characteristics, eosinophilic COPD) are even smaller markets.
Drug companies spread their R&D investment across the number of patients who will use the drug. Developing a monoclonal antibody through preclinical research, multiple phases of clinical trials, and regulatory approval typically takes well over a decade and costs hundreds of millions to billions of dollars. When the eligible patient population is relatively small, each patient’s share of that investment is larger. A blood pressure medication taken by tens of millions of people can be priced low and still recoup costs. A biologic used by a few hundred thousand people cannot.
Limited Competition Keeps Prices High
Nucala competes with only a handful of other biologics that target the same pathway. A 2018 analysis by the Institute for Clinical and Economic Review found annual wholesale costs of $37,293 for Nucala, $31,637 for reslizumab (Cinqair), and $30,889 for benralizumab (Fasenra). All three are expensive, and none undercuts the others dramatically.
This is typical of biologic markets. Unlike generic pills, which can drive prices down by 80% or more after a patent expires, biosimilars (the biologic equivalent of generics) are far harder and more expensive to develop. A generic version of a chemical drug just needs to match the original molecule. A biosimilar has to demonstrate that its living-cell-produced protein behaves similarly to the original, requiring its own clinical trials and a complex regulatory pathway. No biosimilar for Nucala exists yet, and the small number of competing branded biologics don’t create the kind of price pressure you see in markets with dozens of generic options.
US Prices vs. the Rest of the World
The US pricing system amplifies the cost. In the United Kingdom, the list price for Nucala is £840 per dose (roughly $1,050), and the National Health Service has negotiated a confidential discount on top of that. The US list price of nearly $4,000 per dose is roughly four times higher.
This gap exists because most other developed countries have government agencies that negotiate drug prices directly with manufacturers, using cost-effectiveness analyses to set acceptable thresholds. The US historically has not done this for most drugs. Manufacturers set their own list prices, and the negotiation happens piecemeal between drugmakers, pharmacy benefit managers, and individual insurers. The result is consistently higher prices for the same drug in the US compared to peer countries.
Insurance Gatekeeping Reflects the Cost
Because Nucala is so expensive, insurers put significant barriers in place before approving it. Prior authorization for Nucala typically requires documented proof that cheaper treatments have already failed. For eosinophilic asthma, insurers like Johns Hopkins Health Plans require a baseline blood eosinophil count of at least 150 cells per microliter, plus evidence that you’re already on optimized doses of an inhaled corticosteroid and at least one additional controller medication.
The criteria get more specific for other conditions. For nasal polyps, you generally need documented bilateral polyps that have persisted despite at least four weeks of nasal corticosteroid treatment, plus either prior sinus surgery or failed systemic steroid courses. For hypereosinophilic syndrome, insurers require an eosinophil count of at least 1,000 cells per microliter, a stable dose of existing therapy, and a diagnosis lasting at least six months.
These requirements serve a dual purpose. They ensure the drug goes to patients most likely to benefit, and they limit the insurer’s financial exposure. If your insurance denies initial coverage, it’s usually because one of these specific boxes hasn’t been checked in your medical records rather than a blanket refusal. Working with your prescribing doctor to document each criterion is often the key to getting approval.
What You Actually Pay
The $48,000 annual list price is rarely what insured patients pay directly. Most commercial insurance plans cover Nucala as a specialty medication with a copay or coinsurance structure, though even 10% coinsurance on a $4,000 dose adds up quickly. GSK operates a copay assistance program that can reduce out-of-pocket costs for commercially insured patients, sometimes to as little as $0 per dose. Medicare patients don’t qualify for manufacturer copay cards but may find support through independent foundations.
If you’re uninsured, the list price applies in full unless you qualify for GSK’s patient assistance program, which provides the drug at no cost to eligible patients below certain income thresholds. The gap between the sticker price and what most patients actually pay is enormous, but navigating that gap requires paperwork, phone calls, and patience.